Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
Study met primary and all key secondary efficacy endpoints Participants receiving DT120 ODT achieved a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) score, with...
Announced positive topline results from Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), demonstrating rapid, robust, and durable efficacy Topline...
Barchart Research What to Expect from DFTX Earnings DFTX Generated August 5, 2026 Current Price $44.39 EPS Estimate $$-0.55 Consensus Rating Strong Buy Average Move 4.78% Definium's First Profitable Quarter...
Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...
Barchart Research What to Expect from DFTX Earnings DFTX Generated July 29, 2026 Current Price $42.13 EPS Estimate $$-0.55 Consensus Rating Strong Buy Average Move 4.78% Definium Therapeutics: Four Straight...
Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervasive, and debilitating symptoms 1,2,3 Patients experience high rates...
Data highlight the challenges of achieving response and sustained remission in newly diagnosed and established GAD patients with existing therapies